Expanding the spectrum of white matter abnormalities in Wolfram syndrome: A retrospective review

Justin Simo, Heather M. Lugar, Elka Miller, Adi Wilf-Yarkoni, Yael Goldberg, Ayça Kocaağa, Shoichi Ito, Sirio Cocozza, Giulio Frontino, Cristina Baldoli, Aziz Benbachir, Catherine Ashton, Guy Rouleau, Tamara Hershey, Yann Nadjar, Roberta La Piana
doi: https://doi.org/10.1101/2024.08.31.24312796

Abstract

Background and Objectives Wolfram syndrome (WFS) is a genetic disorder mainly caused by pathogenic variants in the WFS1 gene. It is characterized clinically by optic atrophy (OA), diabetes mellitus (DM), sensorineural hearing loss (SNHL), diabetes insipidus (DI), and variable neurological/psychiatric symptoms. WFS typically manifests before age 20 and progresses into adulthood. Classical neuroradiological features include cerebellar and/or brainstem atrophy as well as white matter abnormalities ranging from small, ovoid lesions to diffuse, symmetrical changes along the visual pathway. Following the identification of multifocal, progressive white matter abnormalities that prompted the consideration of multiple sclerosis (MS) in two molecularly confirmed WFS subjects, we sought to verify whether MS-like lesions constitute a novel WFS-associated MRI pattern.

Methods We conducted an international multicenter retrospective study of the clinical, genetic, and radiological data from 17 unrelated WFS subjects.

Results Seven subjects (7/17; 41%) showed at least one focal white matter lesion evocative of MS. Among these seven, three fulfilled the McDonald radiological criteria of dissemination in space and time, suggesting an inflammatory demyelinating process. All subjects reviewed in the study had at least one of the classical WFS MRI features.

Conclusions Our report expands the WFS spectrum of white matter involvement to include progressive, seemingly inflammatory demyelinating lesions. While we cannot exclude the possibility of a WFS-MS dual diagnosis in some cases, the role of WFS1 in myelination suggests a selective white matter vulnerability in WFS. Our findings suggest that follow up MRI should be recommended to adult subjects with WFS. Further identification and longitudinal study of adult WFS subjects is required to confirm whether a WFS molecular diagnosis confers susceptibility to the development of MS.

1 Introduction

Wolfram syndrome (WFS) is a rare genetic spectrum disorder characterized clinically as any combination of optic atrophy (OA), diabetes mellitus (DM), diabetes insipidus (DI), and sensorineural hearing loss (SNHL), accompanied by other neurological and/or psychiatric features1–4. These latter features, seen in over 50% of cases, are usually progressive and include cerebellar ataxia, brainstem dysfunction, epilepsy, and cognitive disability3. Biallelic or monoallelic pathogenic variants in WFS1 cause WFS, putatively through loss-of-function mechanisms that undermine endoplasmic reticulum (ER)-mitochondria dynamics and trigger unfolded protein response (UPR)-mediated cell death5–11.

From a neuroimaging perspective, although different CNS structures are involved, the most common imaging findings reported in WFS are cerebellar atrophy, brainstem atrophy, and signal changes along the visual pathway, posterior pituitary gland, pontine fibers, and cerebral white matter12–15. In particular, the patterns of white matter abnormalities range from small multifocal, ovoid-shaped T2-hyperintense lesions to symmetrical, diffuse involvement12–17. MRI findings in WFS can appear as early as the first decade, even when neurological symptoms are absent or barely noticeable, and they progress over time3,9,10,12,18. Interestingly, they seem to be coupled to more profound abnormalities that can be detected through advanced imaging techniques. These include microstructural alterations of the white matter in early myelinating structures (i.e., brainstem, posterior periventricular white matter), fueling the hypothesis that hypomyelination may play a role and precede adult stage neurodegeneration in WFS9,10,14.

In agreement with conventional and advanced neuroimaging findings that indicate white matter involvement in WFS, molecular studies strongly suggest that WFS1 could play a vital role in establishing and maintaining white matter integrity17,19–24. To this end, it has been speculated that the pathophysiology of CNS features in WFS could at least in part overlap that of more common demyelinating diseases, such as multiple sclerosis (MS)14. In line with these speculations, and after identifying two unrelated, genetically confirmed WFS subjects through the White Matter Rounds Network25, in which multifocal, progressive, and contrast-enhancing white matter abnormalities led to the consideration of MS, we aimed to assess the prevalence of likely inflammatory white matter lesions and MS diagnosis in subjects with WFS.

2 Materials and methods

2.1 Participants

We conducted an international, multicenter retrospective review of the clinical, neuroradiological, and molecular data of subjects with the following inclusion criteria:

  1. Clinical diagnosis of WFS, defined as the presence of:

    1. At least two of the four classical WFS features (OA, DM, DI, and SNHL).

    2. At least one neurological or psychiatric symptom in addition to SNHL and OA.

      Patients with Wolfram-like syndrome (at least one classical feature plus one neurological/psychiatric symptom aside from SNHL and OA) were included if they had a positive WFS family history.

  2. If above criterion not met, genetic diagnosis molecularly confirmed by detection of pathogenic or likely pathogenic variants in the WFS1 gene, classified according to ACMG guidelines26, through an accredited clinical diagnostic laboratory.

  3. Available brain MRI with axial and sagittal T2-weighted and T2-FLAIR images at minimum. Any additional brain MR sequences or spinal cord images for subjects meeting this minimum requirement were also reviewed.

To achieve this, we contacted the corresponding authors of previously published WFS case reports and series (150 subjects). Ten authors responded and agreed to participate. We therefore included 17 subjects from seven countries: Canada (1), France (1), Israel (2), USA (8), Italy (3), Turkey (1), and Japan (1).

2.2. Data Analysis

For each included subject, we collected the following demographic and clinical data: sex, family history, age at onset (defined as the age at which at least one WFS classical feature or neurological/psychiatric deficit appeared), age at latest examination, and presence of ataxia/cerebellar signs, spasticity, abnormal reflexes, other movement disorders, cranial nerve dysfunction, vertigo, tinnitus, migraine, neuropathy, seizures, psychiatric disorders, cognitive deficits, sphincter dysfunction, and extra-neurological signs.

The MRI images were reviewed independently by two teams of raters:

  1. JS and RLP, with >15 years of experience in white matter disorders.

  2. A neuroradiologist from each participating institution (SC/GF-CB for cases from Italy, AWY-YG for cases from Israel, AK for the case from Turkey, and SI for the case from Japan) or a neuroradiologist from outside the study (EM, with >20 years of experience, for all cases from Canada, USA, and France).

When available, for 10 subjects (10/17; 58.8% of the entire cohort), each MRI scan was re-evaluated four months later, blind to the initial MRI interpretation, with a focus on the multifocal white matter abnormalities documented in each subject. The raters remained blind to the clinical data during each review session to further mitigate lesion classification bias. Disagreements between raters were resolved by consensus.

We performed a qualitative analysis of all available MRI images to assess the presence and characteristics of the white matter abnormalities. The following criteria were analyzed: location (periventricular, subcortical, juxtacortical), lobar involvement (frontal, temporal, parietal, occipital, cerebellar), pattern of involvement (multifocal, confluent, diffuse), symmetry, and enhancement following gadolinium injection. In our study, a lesion was defined as a focal area of T2-hyperintense signal in the CNS white matter. Juxtacortical lesions were defined as lesions in direct contact with the cortical ribbon. Periventricular lesions included all lesions abutting any portion of lateral ventricles as well as intracallosal lesions and linear plate-like bandings. Subcortical lesions were defined as supratentorial non-juxtacortical, non-periventricular white matter lesions. MS-like lesions were defined as round/ovoid areas of T2-hyperintense signal at least 3mm in long axis27–29. MR images were also evaluated for cerebral, brainstem, and cerebellar (hemispheric and vermian) atrophy and when possible, depending on the available sequences, other associated features such as gray matter involvement, microvascular changes, and calcifications. When spinal cord MRI was available, we evaluated it for the presence of signal abnormalities and atrophy. Given the nature of this retrospective review, there were intrinsic limitations in the analysis, as MRI examinations slightly differed in imaging quality and techniques.

2.3 Standard Protocol Approvals, Registrations, and Patient Consent

Access to patient medical histories and results of diagnostic investigations for collaborative retrospective study was granted by the review boards of each participating institution, in conformity to respective anonymization procedures.

3 Results

Table 1 contains the clinical, genetic, and radiological data from the 17 included subjects.

View this table:
Table 1. Clinical, genetic, and neuroradiological data compiled from 17 WFS subjects.

Legend: A = ataxia and/or other cerebellar signs; B = bladder dysfunction; BA = brainstem atrophy; C = cataract; CA = cerebellar atrophy; Cal = callosal/pericallosal; CD = cognitive deficit; Cer = cerebellar white matter/peduncles; C Het = compound heterozygous; D = diffuse/confluent involvement of the centrum semiovale and/or peritrigonal white matter; DCo = diabetic coma; DI = diabetes insipidus; DM = diabetes mellitus; DN = diabetic neuropathy; Het = heterozygous; Hom = homozygous; Hyperr = hyperreflexia; Hypor = hyporeflexia; JxU = juxtacortical/U-fiber; LP = lumbar puncture; M = migraine; Mo = other motor issues; MS = multiple sclerosis; N/A= not available; N/P = not performed; OA = optic atrophy; OCBs = oligoclonal bands; Pit = absent/diminished posterior pituitary bright spot; PN = peripheral neuropathy; Po = pontine signal changes; Psy = psychiatric symptoms; Pun = punctate subcortical white matter foci typical of WFS; PV = periventricular; PVp = diffuse, bilateral signal changes in posterior horn periventricular white matter and/or optic radiations; S = seizures; SC = spinal cord; SNHL = sensorineural hearing loss; Sp = spasticity; Sub = subcortical; WBCs = white blood cells; † = focal lesion(s) ultimately categorized as intermediate (in between WFS and MS); ** = McDonald radiological criteria fulfilled.

3.1 Clinical findings

Demographic and clinical data were available for 16/17 subjects (94.1%); for one subject the only information was the sex, the age at last examination, and the confirmed molecular diagnosis. The cohort included nine female subjects (52.9%). Median age at onset of WFS was 15.5 years (range = 3-35 years). Regarding classical WFS features, nearly all exhibited OA (n = 15/16; 94%) except for one subject (#2), who had diminished visual acuity with a normal fundoscopic examination. Thirteen had DM (n = 13/16; 81%), nine had SNHL (n = 9/16; 57%), and seven had DI (n = 7/16; 44%). In all subjects except subject #11, for whom the first sign was non-syndromic epilepsy, the first sign(s) included one or multiple classical WFS features (n = 15/16; 94%), most commonly DM. Two subjects, #3 and #15, developed cataract, an uncommon, yet known WFS feature, at some point in the clinical course (n = 2/16; 13%).

Neurological and/or psychiatric symptoms, aside from OA and SNHL, manifesting several years post-onset (median = 6 years; range = 3-42 years), were documented in all subjects (n = 16/16; 100%), consistent with the neurodegenerative character of WFS.

Two subjects, #2 and #3 (n = 2/16; 13%), presented acute focal deficits in the third/fourth decade that may be related to active demyelination as shown on MRI. These included hyperreflexia and fine motor impairment (subject #2) and truncal ataxia, appendicular ataxia, and dysarthria (subject #3).

3.2. Genetic findings

Pathogenic or likely pathogenic variants in WFS1 (mono-or biallelic) were documented in all subjects for whom genetic testing had been performed (n = 16 tested/17 total; 94%). Subject #15 was diagnosed with Wolfram-like syndrome after detection of a monoallelic pathogenic WFS1 variant through whole genome sequencing, which was performed because of unusual MRI features.

Family history was noteworthy for symptoms along the WFS spectrum in most subjects for whom this information was available (n = 10/15; 66%). The family history was positive for WFS in three cases (n = 3/15; 20%), cataract in three (n = 3/15; 20%), and cardiac anomalies/syndromes in two (n = 2/15; 13%), which have also been reported in WFS.

3.3. Neuroimaging findings

The mean age at the latest MRI available for review was 29 years old (range = 14-60 years). All subjects demonstrated at least one neuroradiological feature typical of WFS (Figure 1)12–15. For 11 subjects (n = 11/17; 65%), two timepoints were available for assessment (mean follow-up MRI duration = 5.3 years).

Figure 1.
Figure 1. Classical MRI features associated with WFS.

A, Axial T2-weighted image showing bilateral pontine signal abnormality (subject #10). B, Axial T2-FLAIR image showing bilateral symmetric posterior white matter abnormal signal as well as a punctate, round white matter signal abnormality in the left frontal lobe (subject #14).

Classical WFS-associated features

Involvement of the posterior periventricular white matter and/or optic radiations was the most common finding (n = 15/17; 88%), followed by punctate subcortical white matter changes (n = 9/17; 53%), pontine signal changes (n = 7/17; 41%), brainstem atrophy (n = 6/17; 35%), cerebellar atrophy (n = 5/17; 29%), diffuse/confluent involvement of the centrum semiovale and/or peritrigonal white matter (n = 4/17; 24%), and absent/diminished T1-weighted posterior pituitary bright spot (n = 1/17; 6%).

Enlarged perivascular spaces (n = 3/17; 18%), corpus callosum abnormalities (n = 3/17; 18%), midbrain signal changes (n = 2/17; 12%), and abnormal occipital lobe gyrification with or without posterior horn ventricular enlargement (n = 2/17; 12%) were additionally observed.

MS-like white matter abnormalities

We detected T2-hyperintense white matter foci that were MS plaque-like27–29 in seven subjects (n = 7/17; 41%) (Figures 2 and 3). In four of these subjects (n = 4/17; 24%), the McDonald radiological criteria of dissemination in space and time were either fully (n = 3) or partially (n = 1) fulfilled, inciting consideration of a WFS-MS double diagnosis (Figure 2)27. Some lesions in three of these four subjects showed gadolinium enhancement on T1-weighted imaging (Figure 2A), further supporting the existence of an underlying inflammatory process. Positive oligoclonal band status strongly supported a secondary diagnosis of MS in the only two subjects for whom lumbar puncture was performed (#2 and #3). In both cases, a secondary diagnosis of MS was communicated, and MS treatment with teriflunomide was initiated in subject #3. Follow-up MRI after teriflunomide initiation documented stabilization of the multifocal white matter lesion load with worsening of pre-existing cerebellar atrophy and diffuse bilateral subcortical white matter involvement (Figure 2G-I). The observed locations and characteristics of MS-like focal lesions are summarized in Table 2.

Figure 2.
Figure 2. Patients with fulfilled or partially fulfilled McDonald criteria.

A, B, and C represent subject #2 (criteria fulfilled). A, Axial T2-FLAIR image showing multifocal periventricular, callosal, and subcortical white matter lesions (arrows) with accompanying diffuse abnormal peritrigonal white matter signal (circle). B, Post-gadolinium axial T1 image showing an enhancing callosal lesion. C, Sagittal T2 image of the cervical and thoracic spinal cord showing a demyelinating lesion at the level of C3. D, E, and F represent subject #1 (criteria partially fulfilled). D, Axial T2-FLAIR showing an oval-shaped lesion in the left temporal subcortical white matter. E, Axial T2-FLAIR showing a periventricular lesion around the frontal horn of the right lateral ventricle. F, Axial T2-FLAIR, performed seven years after the first exam (D, E), showing new focal white matter lesions in the right insula, right periventricular white matter, and along the posterior horn of the right lateral ventricle. G, H, and I represent subject #3 (criteria fulfilled). G, Sagittal T2-FLAIR showing multifocal white matter lesions perpendicular to the ventricular walls. H, Sagittal T2-FLAIR, performed four years after initial MRI (G), demonstrating progression of the lesion burden in both the supra- and infratentorial regions despite treatment with teriflunomide as of the first year in the four-year interval. I, Axial T2 spinal cord MRI showing a white matter lesion located in the left posterior cord at the C3 level.

Figure 3.
Figure 3. White matter abnormalities suggestive of an inflammatory process

(A, B, C) or classified as intermediate (D) in four subjects with WFS. All images are axial T2-FLAIR. A, Elongated lesion located at the level of the anterior horn of the left lateral ventricle (subject #7). B, Small temporal periventricular lesion perpendicular to the right ventricular wall (subject #7). C, Small periventricular lesion perpendicular to the right ventricular wall (subject #10). D, Left insular deep white matter lesion classified as intermediate between suspicious for inflammatory process and typical for WFS (subject #8).

View this table:
Table 2. Distribution of MS plaque-like foci across the seven subjects in which these were identified.

*Only three radiologically MS-like subjects underwent post-contrast imaging.

During blind re-analysis four months after the first image review, it was agreed that three subjects (#7, #8, and #13) had focal lesions not strictly belonging to either category (WFS- or MS-like/demyelinating) (Figure 3D; see Table 1 for initial lesion categorization in each subject). The areas of suspicion were in the subcortical white matter and included two or more small, round, yet non-ovoid T2-hyperintense lesions close to one another. The lesions did not correspond to enlarged perivascular spaces.

4 Discussion

In this study, we report WFS subjects presenting with neuroradiological and, in some cases, clinical profiles compatible with a diagnosis of MS. The identification of four subjects with seemingly inflammatory white matter lesions that fully or partially fulfilled the McDonald criteria for MS diagnosis raises the possibility that a WFS molecular diagnosis may predispose to the development of neuroinflammatory white matter disorders such as MS. In fact, the worldwide prevalence estimates of MS (∼1:2800)30 and WFS (∼1:500 000)31,32 argue against coincidental occurrence of WFS and focal demyelinating events but rather suggest pathophysiological overlap between MS and WFS.

Our series focuses on MR imaging of adult subjects with WFS, who have been far less studied by imaging than pediatric subjects. Our findings suggest that secondary neuroinflammation, even when it does not satisfy the full criteria for MS, might contribute to gradual neurological and/or psychiatric decline in WFS9. Therefore, we recommend follow-up of WFS patients beyond adolescence to monitor the onset of inflammatory demyelinating lesions.

Importantly, multifocal white matter lesions have been previously described in WFS, albeit not with the usual features of MS plaques. Thus, the risk for individuals with Wolfram-like syndrome (i.e., partial WFS) to receive an incorrect primary diagnosis of MS is not negligible given the variability in neurological progression seen across subjects. We recommend that genetic testing for WFS be performed when a subject presents with multifocal white matter lesions – either seemingly inflammatory or not – and at least one of the classic diagnostic features of WFS.

In line with the hypothesis that some subjects in our study may be concomitantly suffering from WFS and MS, subject #3 responded to teriflunomide (Figure 2G-I). This was the only subject in our series who had started disease-modifying therapy for MS. While there is a possibility that the treatment had no impact on the natural course of WFS in this subject, it is plausible that underlying degenerative processes may have been exacerbated while inflammation was being suppressed. Even though the exact mechanisms contributing to this subject’s outcome remain undefined, simultaneous wolframin/WFS1 deficiency and teriflunomide treatment might have imposed a significant mitochondrial stressor. Indeed, Wolframin/WFS1 plays an indirect, yet essential role in multiple facets of mitochondrial quality control putatively through modulation of Ca2+ homeostasis, while the mechanism of action of teriflunomide is the inhibition of dihydroorotate dehydrogenase, whose activity is intrinsically linked to the mitochondrial respiratory chain19,33. Thus, the classic WFS-associated neuroradiological features in this subject might have progressed, at least in part, because of a compounded mitochondrial insult, although dedicated studies are needed to validate this speculation.

Existing molecular evidence insists that unchecked tissue-specific and systemic inflammatory processes are significant drivers of WFS pathogenesis34–38. For example, in the context of DM, several works suggest that loss of wolframin protein (Wfs1) in murine pancreatic β-cells causes ER stress-mediated NLRP3 inflammasome activation and subsequent apoptosis by means of upregulated expression of pro-inflammatory cytokines, namely IL-1β35,37,38. β-cells lacking wolframin in turn show disproportionate increases in ER stress and pro-inflammatory mediator expression in response to applied cytokines and hyperglycemia, forming a positive feedback cycle that likely exacerbates DM in WFS35. In the context of OA, early stage optic nerve demyelination in Wfs1-KO mice is marked by ER stress-mediated STAT3 activation and an overall pro-neuroinflammatory, anti-survival transcriptomic shift in local glial populations34. This shift is associated with a downregulation of glial MCT1 that hampers neuron-bound lactate shuttling capacity, instigating retinal ganglion cell degeneration over time34. Critically, lower expression of MCT1 was additionally detected in the cortex and striatum of the mice, indicating that these neuroinflammatory transcriptomic shifts may tile the entire brain34. Furthermore, in a recent WFS case report, patient-derived peripheral blood mononuclear cells (PBMCs), which were anomalously wolframin-deficient, showed constitutively high, UPR-independent expression of pro-inflammatory cytokines that correlated with hypercytokinemia (TNF-α, IL-1β, and IL-6) and a positively skewed Th17/Treg ratio—signs of systemic inflammation37. A chronic, systemic inflammatory state characterized by hypercytokinemia was also corroborated in a WFS mouse model35. Such findings are particularly intriguing given the large body of evidence implicating Th17 cells in MS pathogenesis, importantly during the acute phase of disease39. Taken together, these studies implicate wolframin in the regulation of parallel inflammatory signaling cascades that are perhaps simultaneously brewing in a WFS individual. Our result of focal enhancement post-contrast being observed in all radiological MS-mimicking subjects for whom this investigation was performed (subjects #2, #3, and #4), when interpreted alongside a potential chronic Th17-driven systemic inflammatory process and generalized neuroinflammatory state, begs the question of whether MS-overlapping pathology could arise in WFS.

In our review, some lesions were interpreted as neither MS-nor WFS-like. In the corresponding subjects, gadolinium administration was not performed, so we do not know whether these lesions could be inflammatory. This observation further supports the idea of a continuum between white matter involvement classically seen in WFS and in neuroinflammation. The identification of signs currently considered specific for MS, namely the central vein sign (CVS), could help in further classifying white matter lesions in WFS40. CVS could not be validated in our subjects due to a lack of susceptibility-weighted imaging sequences, no reconstructible planes, and probably insufficient field strength. Higher field imaging (7T MRI) could prove useful in not only detecting CVS, as demonstrated by a recent study evaluating the diagnostic performance of 3T vs. 7T MRI in MS41, but also in better depicting the signal characteristics of white matter abnormalities in WFS subjects, which may help differentiate WFS from MS by imaging.

A recent prospective study has supported the addition of the optic nerve as a fifth CNS location within the McDonald radiological criterion of dissemination in space42. Since dedicated optic nerve MRI was only performed in one subject from our cohort (who did not have a confirmed molecular diagnosis), and as mentioned, adult WFS subjects have been far less studied than pediatric subjects, the prevalence of optic nerve lesions in the adult WFS population remains unknown. Consequently, the proportion of WFS patients who will satisfy MS diagnostic criteria because of the proposed modification to the criteria cannot be estimated at this time.

Our study has several limitations, namely its retrospective nature (which precluded the use of advanced imaging techniques), the obstacles related to the identification and inclusion of adult WFS patients, and the lack of follow-up MRI in a considerable number of subjects. Future prospective imaging studies can help clarify the nature of white matter involvement in adult patients with WFS.

In conclusion, our report expands the WFS spectrum of white matter involvement to include late-onset progressive, seemingly inflammatory demyelinating lesions that, in the context of supportive clinical and laboratory findings, can prompt consideration of MS. We emphasize the need for continuous radiological follow-up of WFS patients into early and middle adulthood, and the utility of international collaboration in this regard, for better characterization of age- and/or immune-related MRI patterns. In the future, these results may lead to the inclusion of WFS to the growing list of single-gene disorders with the potential to mimic or confer susceptibility to MS43,44.

Data Availability

All data produced in the present study are available upon reasonable request to the authors.

5 Conflict of Interest

The authors have no conflicts of interest to declare.

6 Author Contributions

JS: manuscript writing and project coordination (contacting WFS authors, collection, compilation, and analysis of data, via conference call or email correspondence, from all authors who accepted to collaborate). EM: external neuroradiologist invited for MRI review. HML & TH: data collection from WFS cohort followed at Washington University, USA (eight subjects). AWY & YG: data collection from two WFS subjects followed at Tel Aviv University, Israel. AK: data collection from one Wolfram-like syndrome subject followed at Eskisehir City Hospital, Turkey. SI: data collection from one WFS subject followed at Chiba University, Japan. SC: data collection from one WFS subject seen at University of Naples “Federico II,” Italy. GF & CB: data collection from two subjects, derived from a larger cohort of 16 pre-screened WFS subjects (of which six were adults) seen at San Raffaele Hospital, Italy. AB: analysis of compiled data. CA, GR, & RLP: data collection from one WFS subject followed at McGill University, Canada. YN: data collection from one WFS subject followed at Pitié-Salpêtrière University Hospital, France. RLP: conceptualization of the study, analysis of compiled data, funding acquisition, and review and editing of the manuscript.

7 Funding

JS has received scholarships from the Canadian Institutes of Health Research (CIHR) and the Fonds de Recherche du Québec en Santé (FRQS). RLP has received a Research Scholar Junior 1 award from the FRQS, research funds from the Canadian Radiological Foundation, the Spastic Paraplegia Foundation, and received funds for further data on this project from Hoffman-La Roche Limited.

8 Acknowledgment

This work would not have been possible without our international collaborators, who are members of the White Matter Rounds Network:

“Adult genetic leukoencephalopathies are rare neurological disorders that present unique diagnostic challenges due to their clinical and radiological overlap with more common white matter diseases, notably multiple sclerosis (MS). In this context, a strong collaborative multidisciplinary network is beneficial for shortening the diagnostic odyssey of these patients and preventing misdiagnosis. The White Matter Rounds (WM Rounds) are multidisciplinary international online meetings attended by more than 30 physicians and scientists from 15 participating sites that gather every month to discuss patients with atypical white matter disorders. […] The WM Rounds Network demonstrate[s] the value of collaborative multidisciplinary international case discussion meetings in differentiating and preventing misdiagnoses between genetic white matter diseases and atypical MS.”

  • Huang YT, et al. The White Matter Rounds experience: The importance of a multidisciplinary network to accelerate the diagnostic process for adult patients with rare white matter disorders. Front. Neurol. (2022) 13:928493. doi: 10.3389/fneur.2022.928493

References

  1. 1.↵
    Barrett T, Bundey SE, Macleod AF. ( DIDMOAD ) syndrome UK nationwide study of Wolfram. Lancet. 1995;346:1458–1463.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.
    Shannon P, Becker L, Deck J. Evidence of widespread axonal pathology in Wolfram syndrome. Acta Neuropathol. 1999;98(3):304–308. doi:10.1007/s004010051084
    OpenUrlCrossRefPubMed
  3. 3.↵
    Chaussenot A, Bannwarth S, Rouzier C, et al. Neurologic features and genotype-phenotype correlation in Wolfram syndrome. Ann Neurol. 2011;69(3):501–508. doi:10.1002/ana.22160
    OpenUrlCrossRefPubMed
  4. 4.↵
    Urano F. Wolfram Syndrome: Diagnosis, Management, and Treatment. Curr Diab Rep. 2016;16(1):1–8. doi:10.1007/s11892-015-0702-6
    OpenUrlCrossRef
  5. 5.↵
    Inoue H, Tanizawa Y, Wasson J, et al. A gene encoding a transmembrane protein is mutated in patients with diabetes mellitus and optic atrophy (Wolfram syndrome). Nat Genet. 1998;20(2):143–148. doi:10.1038/2441
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.
    Amr S, Heisey C, Zhang M, et al. A homozygous mutation in a novel zinc-finger protein, ERIS, is responsible for Wolfram syndrome 2. Am J Hum Genet. 2007;81(4):673–683. doi:10.1086/520961
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.
    Bai X, Lv H, Zhang F, et al. Identification of a novel missense mutation in the WFS1 gene as a cause of autosomal dominant nonsyndromic sensorineural hearing loss in all-frequencies. Am J Med Genet Part A. 2014;164(12):3052–3060. doi:10.1002/ajmg.a.36760
    OpenUrlCrossRef
  8. 8.
    Rouzier C, Moore D, Delorme C, et al. A novel CISD2 mutation associated with a classical Wolfram syndrome phenotype alters Ca2+ homeostasis and ER-mitochondria interactions. Hum Mol Genet. 2017;26(9):1599–1611. doi:10.1093/hmg/ddx060
    OpenUrlCrossRef
  9. 9.↵
    Samara A, Rahn R, Neyman O, et al. Developmental hypomyelination in Wolfram syndrome: New insights from neuroimaging and gene expression analyses. Orphanet J Rare Dis. 2019;14(1):1–14. doi:10.1186/s13023-019-1260-9
    OpenUrlCrossRefPubMed
  10. 10.↵
    Loncke J, Vervliet T, Parys JB, Kaasik A, Bultynck G. Uniting the divergent Wolfram syndrome–linked proteins WFS1 and CISD2 as modulators of Ca2+ signaling. Sci Signal. 2021;14(702). doi:10.1126/scisignal.abc6165
    OpenUrlCrossRef
  11. 11.↵
    Zmyslowska A, Kuljanin M, Malachowska B, et al. Multiomic analysis on human cell model of wolfram syndrome reveals changes in mitochondrial morphology and function. Cell Commun Signal. 2021;19(1):1–14. doi:10.1186/s12964-021-00791-2
    OpenUrlCrossRef
  12. 12.↵
    Hershey T, Lugar HM, Shimony JS, et al. Early brain vulnerability in Wolfram syndrome. PLoS One. 2012;7(7). doi:10.1371/journal.pone.0040604
    OpenUrlCrossRefPubMed
  13. 13.
    Lugar HM, Koller JM, Rutlin J, et al. Neuroimaging evidence of deficient axon myelination in Wolfram syndrome. Sci Rep. 2016;6(February):1–13. doi:10.1038/srep21167
    OpenUrlCrossRefPubMed
  14. 14.↵
    Lugar HM, Koller JM, Rutlin J, et al. Evidence for altered neurodevelopment and neurodegeneration in Wolfram syndrome using longitudinal morphometry. Sci Rep. 2019;9(1):1–11. doi:10.1038/s41598-019-42447-9
    OpenUrlCrossRefPubMed
  15. 15.↵
    Samara A, Lugar HM, Hershey T, Shimony JS. Longitudinal assessment of neuroradiologic features in wolfram syndrome. Am J Neuroradiol. 2020;41(12):2364–2369. doi:10.3174/ajnr.A6831
    OpenUrlAbstract/FREE Full Text
  16. 16.
    Labauge P, Renard D, Chaussenot A, Paquis-Flucklinger V. Wolfram syndrome associated with leukoencephalopathy. J Neurol Neurosurg Psychiatry. 2010;81(8):928. doi:10.1136/jnnp.2009.185579
    OpenUrlFREE Full Text
  17. 17.↵
    Kocaaga A, Yimenicioglu S, Bayav M. A .Val412Serfs pathogenic variant associated with Wolfram-like syndrome and leukodystrophy. Egypt J Neurol Psychiatry Neurosurg. 2023;59(1):4–9. doi:10.1186/s41983-023-00608-8
    OpenUrlCrossRef
  18. 18.↵
    Wilf-Yarkoni A, Shor O, Fellner A, et al. Mild Phenotype of Wolfram Syndrome Associated With a Common Pathogenic Variant Is Predicted by a Structural Model of Wolframin. Neurol Genet. 2021;7(2):e578. doi:10.1212/nxg.0000000000000578
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    Cagalinec M, Liiv M, Hodurova Z, et al. Role of Mitochondrial Dynamics in Neuronal Development: Mechanism for Wolfram Syndrome. PLoS Biol. 2016;14(7):1–28. doi:10.1371/journal.pbio.1002511
    OpenUrlCrossRefPubMed
  20. 20.
    Plaas M, Seppa K, Reimets R, et al. Wfs1-deficient rats develop primary symptoms of Wolfram syndrome: Insulin-dependent diabetes, optic nerve atrophy and medullary degeneration. Sci Rep. 2017;7(1):1–16. doi:10.1038/s41598-017-09392-x
    OpenUrlCrossRefPubMed
  21. 21.
    Sakakibara Y, Sekiya M, Fujisaki N, Quan X, Iijima KM. Knockdown of wfs1, a fly homolog of Wolfram syndrome 1, in the nervous system increases susceptibility to age- and stress-induced neuronal dysfunction and degeneration in Drosophila. PLoS Genet. 2018;14(1):1–25. doi:10.1371/journal.pgen.1007196
    OpenUrlCrossRef
  22. 22.
    Chen YF, Kao CH, Chen YT, et al. Cisd2 deficiency drives premature aging and causes mitochondria-mediated defects in mice. Genes Dev. 2009;23(10):1183–1194. doi:10.1101/gad.1779509
    OpenUrlAbstract/FREE Full Text
  23. 23.
    Pourtoy-Brasselet S, Sciauvaud A, Boza-Moran MG, et al. Human iPSC-derived neurons reveal early developmental alteration of neurite outgrowth in the late-occurring neurodegenerative Wolfram syndrome. Am J Hum Genet. 2021;108(11):2171–2185. doi:10.1016/j.ajhg.2021.10.001
    OpenUrlCrossRef
  24. 24.↵
    Kitamura RA, Maxwell KG, Ye W, et al. Multidimensional analysis and therapeutic development using patient iPSC–derived disease models of Wolfram syndrome. JCI Insight. 2022;7(18). doi:10.1172/jci.insight.156549
    OpenUrlCrossRef
  25. 25.↵
    Huang YT, Giacomini PS, Massie R, et al. The White Matter Rounds experience: The importance of a multidisciplinary network to accelerate the diagnostic process for adult patients with rare white matter disorders. Front Neurol. 2022;13. doi:10.3389/fneur.2022.928493
    OpenUrlCrossRef
  26. 26.↵
    Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405–424. doi:10.1038/gim.2015.30
    OpenUrlCrossRefPubMed
  27. 27.↵
    Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162–173. doi:10.1016/S1474-4422(17)30470-2
    OpenUrlCrossRefPubMed
  28. 28.
    Rovira À, Wattjes MP, Tintoré M, et al. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process. Nat Rev Neurol. 2015;11(8):471–482. doi:10.1038/nrneurol.2015.106
    OpenUrlCrossRefPubMed
  29. 29.↵
    Filippi M, Preziosa P, Banwell BL, et al. Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines. Brain. 2019;142(7):1858–1875. doi:10.1093/brain/awz144
    OpenUrlCrossRefPubMed
  30. 30.↵
    Walton C, King R, Rechtman L, et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler. 2020;26(14):1816–1821. doi:10.1177/1352458520970841
    OpenUrlCrossRefPubMed
  31. 31.↵
    Rigoli L, Caruso V, Salzano G, Lombardo F. Wolfram Syndrome 1: From Genetics to Therapy. Int J Environ Res Public Health. 2022;19(6). doi:10.3390/ijerph19063225
    OpenUrlCrossRef
  32. 32.↵
    Rigoli L, Bramanti P, Di Bella C, De Luca F. Genetic and clinical aspects of Wolfram syndrome 1, a severe neurodegenerative disease. Pediatr Res. 2018;83(5):921–929. doi:10.1038/pr.2018.17
    OpenUrlCrossRef
  33. 33.↵
    Hauser SL, Cree BAC. Treatment of Multiple Sclerosis: A Review. Am J Med. 2020;133(12):1380–1390.e2. doi:10.1016/j.amjmed.2020.05.049
    OpenUrlCrossRefPubMed
  34. 34.↵
    Rossi G, Ordazzo G, Vanni NN, et al. MCT1-dependent energetic failure and neuroinflammation underlie optic nerve degeneration in Wolfram syndrome mice. Elife. 2023;12:1–25. doi:10.7554/eLife.81779
    OpenUrlCrossRef
  35. 35.↵
    Morikawa S, Blacher L, Onwumere C, Urano F. Loss of Function of WFS1 Causes ER Stress-Mediated Inflammation in Pancreatic Beta-Cells. Front Endocrinol (Lausanne). 2022;13(March):1–12. doi:10.3389/fendo.2022.849204
    OpenUrlCrossRef
  36. 36.
    Fonseca SG, Ishigaki S, Oslowski CM, et al. Wolfram syndrome 1 gene negatively regulates ER stress signaling in rodent and human cells. J Clin Invest. 2010;120(3):744–755. doi:10.1172/JCI39678
    OpenUrlCrossRefPubMedWeb of Science
  37. 37.↵
    Panfili E, Mondanelli G, Orabona C, et al. Novel mutations in the WFS1 gene are associated with Wolfram syndrome and systemic inflammation. Hum Mol Genet. 2021;30(3-4):265–276. doi:10.1093/hmg/ddab040
    OpenUrlCrossRefPubMed
  38. 38.↵
    Oslowski CM, Hara T, O’Sullivan-Murphy B, et al. Thioredoxin-interacting protein mediates ER stress-induced β cell death through initiation of the inflammasome. Cell Metab. 2012;16(2):265–273. doi:10.1016/j.cmet.2012.07.005
    OpenUrlCrossRefPubMedWeb of Science
  39. 39.↵
    Moser T, Akgün K, Proschmann U, Sellner J, Ziemssen T. The role of TH17 cells in multiple sclerosis: Therapeutic implications. Autoimmun Rev. 2020;19(10):102647. doi:10.1016/j.autrev.2020.102647
    OpenUrlCrossRef
  40. 40.↵
    Maggi P, Absinta M, Grammatico M, et al. Central vein sign differentiates Multiple Sclerosis from central nervous system inflammatory vasculopathies. Ann Neurol. 2018;83(2):283–294. doi:10.1002/ana.25146
    OpenUrlCrossRefPubMed
  41. 41.↵
    Okromelidze L, Patel V, Singh RB, et al. Central Vein Sign in Multiple Sclerosis: A Comparison Study of the Diagnostic Performance of 3T versus 7T MRI. Am J Neuroradiol. 2024;45(1):76–81. doi:10.3174/ajnr.A8083
    OpenUrlAbstract/FREE Full Text
  42. 42.↵
    Vidal-Jordana A, Rovira A, Calderon W, et al. Adding the Optic Nerve in Multiple Sclerosis Diagnostic Criteria: A Longitudinal, Prospective, Multicenter Study. Neurology. 2024;102(1). doi:10.1212/WNL.0000000000207805
    OpenUrlCrossRef
  43. 43.↵
    Weisfeld-Adams JD, Sand IBK, Honce JM, Lublin FD. Differential diagnosis of Mendelian and mitochondrial disorders in patients with suspected multiple sclerosis. Brain. 2015;138(3):517–539. doi:10.1093/brain/awu397
    OpenUrlCrossRefPubMed
  44. 44.↵
    Ayrignac X, Carra-Dallière C, Marelli C, Taïeb G, Labauge P. Adult-Onset Genetic Central Nervous System Disorders Masquerading as Acquired Neuroinflammatory Disorders: A Review. JAMA Neurol. 2022;79(10):1069–1078. doi:10.1001/jamaneurol.2022.2141
    OpenUrlCrossRef
  45. 45.
    De Michele G, Maione L, Cocozza S, et al. Ataxia and Hypogonadism: a Review of the Associated Genes and Syndromes. Cerebellum. 2024;23(2):688–701. doi:10.1007/s12311-023-01549-x
    OpenUrlCrossRef
  46. 46.
    Ito S, Sakakibara R, Hattori T. Wolfram syndrome presenting marked brain MR imaging abnormalities with few neurologic abnormalities. Am J Neuroradiol. 2007;28(2):305–306.
    OpenUrlPubMed
Back to top
Posted September 01, 2024.
Download PDF
Data/Code
Email
Expanding the spectrum of white matter abnormalities in Wolfram syndrome: A retrospective review
Justin Simo, Heather M. Lugar, Elka Miller, Adi Wilf-Yarkoni, Yael Goldberg, Ayça Kocaağa, Shoichi Ito, Sirio Cocozza, Giulio Frontino, Cristina Baldoli, Aziz Benbachir, Catherine Ashton, Guy Rouleau, Tamara Hershey, Yann Nadjar, Roberta La Piana
medRxiv 2024.08.31.24312796; doi: https://doi.org/10.1101/2024.08.31.24312796
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area